Dengue vaccine: hypotheses to understand CYD-TDV-induced protection (Q42985743)

12 November 2017

title

Dengue vaccine: hypotheses to understand CYD-TDV-induced protection (English)

1 reference

12 November 2017

0 references

1 reference

1 reference

Bruno Guy

1

1 reference

12 November 2017

Nicholas Jackson

series ordinal

2

1 reference

12 November 2017

language of work or name

English

0 references

publication date

7 December 2015

1 reference

Nature Reviews Microbiology

12 November 2017

published in

1 reference

12 November 2017

volume

14

1 reference

12 November 2017

issue

1

1 reference

12 November 2017

page(s)

45-54

1 reference

The global distribution and burden of dengue

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Epidemiological risk factors associated with high global frequency of inapparent dengue virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

21 January 2018

Dengue viral infections

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Immune response to dengue virus and prospects for a vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Efficacy of a tetravalent dengue vaccine in children in Latin America.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Innate immunity to dengue virus infection and subversion of antiviral responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Determinants of inapparent and symptomatic dengue infection in a prospective study of primary school children in Kamphaeng Phet, Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Reduced risk of disease during postsecondary dengue virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Review article: Research on dengue during World War II revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

B-cell responses during primary and secondary dengue virus infections in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Dominant cross-reactive B cell response during secondary acute dengue virus infection in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Preexisting neutralizing antibody responses distinguish clinically inapparent and apparent dengue virus infections in a Sri Lankan pediatric cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Role of humoral versus cellular responses induced by a protective dengue vaccine candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

CD8+ T cells prevent antigen-induced antibody-dependent enhancement of dengue disease in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Different innate signatures induced in human monocyte-derived dendritic cells by wild-type dengue 3 virus, attenuated but reactogenic dengue 3 vaccine virus, or attenuated nonreactogenic dengue 1-4 vaccine virus strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Dengue virus neutralizing antibody levels associated with protection from infection in thai cluster studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Preventing dengue--is the possibility now a reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Dengue: a continuing global threat

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Immunology. A neighborhood watch upholds local immune protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Virus-specific T lymphocytes home to the skin during natural dengue infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

CD8+ T Cells Can Mediate Short-Term Protection against Heterotypic Dengue Virus Reinfection in Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Dynamics of dengue disease severity determined by the interplay between viral genetics and serotype-specific immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Genetic variants of MICB and PLCE1 and associations with non-severe dengue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

The development of Dengue vaccines. Introduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Research on dengue during World War II

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Dengue serotype cross-reactive, anti-e protein antibodies confound specific immune memory for 1 year after infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Evaluation of interferences between dengue vaccine serotypes in a monkey model.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Vaccine-induced measles virus-specific T cells do not prevent infection or disease but facilitate subsequent clearance of viral RNA.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Acellular pertussis vaccines. Efficacy and evaluation of clinical case definitions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Sensitivity, specificity, and vaccine efficacy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO.2015.2

Innate immune responses in human dendritic cells upon infection by chimeric yellow-fever dengue vaccine serotypes 1-4.

31 March 2020

1 reference

12 December 2020

HLA and other gene associations with dengue disease severity

1 reference

12 December 2020

1 reference

12 December 2020

On the risk of severe dengue during secondary infection: a systematic review coupled with mathematical modeling.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRMICRO.2015.2

1 reference

12 November 2017

1 reference